Brazil OKs fast-track for device and pharma trial applications
This article was originally published in Clinica
Executive Summary
Brazilian proposals to fast-track the licensing-assessment of a large proportion of the clinical trial applications it receives have been approved. Pending the formal publication of the enacted resolution by regulatory agency Anvisa and the precise detail of the policy, the government has issued a statement confirming that applications involving trials already approved in the EU, US, Japan, Australia or Canada will be fast-tracked. As described in a public consultation in May (www.clinica.co.uk, 10 May 2012), the measure is expected to halve the approval time: an estimated 80% of all applications would be processed within 90 days, said Anvisa. At the time, Brazil reported a backlog of over 100 applications. The new regulation will not affect the procedure for assessing the ethical aspects of trial applications, which will remain the responsibility of the national research ethics committee, Conep.
You may also be interested in...
New EU Approvals
The Pink Sheet's list of EU centralized approvals of new active substances has been updated to add two new products, including Ryzneuta, Evive Biotechnology's treatment for chemotherapy-induced neutropenia.
Over The Counter 2 Apr 2024: Analyzing The Spin-Out Trend In Consumer Health, With HBW’s Malcolm Spicer And Tom Gallen
In this episode, HBW Insight’s Europe and US editors bring their expertise to bear on the current the trend towards standalone OTC companies in global consumer health. We look at four major players: Haleon, which separated from GSK almost two years ago; Kenvue, soon to celebrate its first anniversary as a new company; Sanofi Consumer Healthcare, which is poised to split from its pharma parent; and Bayer, which has decided to buck the trend, holding on to its consumer health division. We discuss some of the advantages of becoming a standalone company, for example in leaning into a wider concept of self-care.
EU Must Crack Down Harder On Fake Medical Devices, Says Innovator
Counterfeit copies of LifeVac Europe’s anti-choking devices have been registered on the EU’s EUDAMED database and continue to be sold on third-party platforms. Medtech Insight asked director of sales and marketing Matthew Banagan how the company deals with fake devices and what the authorities must do.